Twist Bioscience CORP

Twist Bioscience announced record revenue of $118.4 million for its fiscal third quarter of 2026, a 23% increase year-over-year, and raised its full-year revenue guidance.

Twist Bioscience announced record revenue of $110.7 million for its fiscal second quarter of 2026, a 19% increase year-over-year, and raised its full-year revenue guidance.

Twist Bioscience Corporation will issue 632,328 shares and $5 million cash to acquire a license, technology, and a 6% ownership stake in Invenra Inc., securing a board seat.

Twist Bioscience Corporation announced the results of its 2026 Annual Meeting, where shareholders re-elected three Class II Directors, approved executive compensation, and ratified Ernst & Young LLP as its independent auditor.

Twist Bioscience reported record first-quarter fiscal 2026 revenue of $103.7 million, a 17% increase year-over-year, and raised its full fiscal year 2026 revenue guidance.

Twist Bioscience reported preliminary first quarter fiscal 2026 revenue of $103.7 million, surpassing its own guidance and growing 17% year-over-year.

Twist Bioscience reports a 19.3% revenue increase for Q2 2026, reaching $110.7 million, but net loss also widened to $44.0 million.

Twist Bioscience Corporation reported a 16.9% increase in Q1 revenue to $103.7 million and a reduced net loss of $30.5 million, driven by strong growth in DNA synthesis and NGS applications.

Twist Bioscience Corporation reported a 16.9% increase in first-quarter revenue to $103.7 million, driven by growth in NGS Applications and DNA Synthesis and Protein Solutions, while narrowing its net loss to $30.5 million.

Twist Bioscience reported a net income of $20.4 million for the quarter ended June 30, 2025, driven by an 18% revenue increase and a significant gain from the sale of its DNA data storage business.

Twist Bioscience's Q2 2025 revenue increased by 23% year-over-year, driven by growth in NGS tools and synthetic genes, while net losses decreased.

Twist Bioscience saw a 24% increase in revenue and improved gross margins in the first quarter of fiscal year 2025, driven by growth in NGS tools and synthetic genes.

Twist Bioscience reported a 20% revenue increase to $376.6 million and significantly reduced its net loss to $77.7 million in fiscal year 2025, driven by strong growth in NGS tools and synthetic genes.

Twist Bioscience's 10-K filing for fiscal year 2024 reveals a 28% increase in revenue, driven by strong performance in NGS tools and synthetic genes, alongside a focus on expanding manufacturing capacity and strategic partnerships.

Patrick John Finn, President and COO of Twist Bioscience Corp, sold 2,238 shares of common stock on July 23, 2026 for $93.89 per share.

Adam Laponis, Chief Financial Officer of Twist Bioscience Corp, sold 2,399 shares of common stock on July 9, 2026 for $94.33 per share.

Emily M. Leproust, CEO of Twist Bioscience Corp, executed a transaction under a Rule 10b5-1 trading plan, selling 18,880 shares of common stock.

Dennis Cho, Senior Vice President at Twist Bioscience, reported a sale of 14,205 shares of common stock on June 24, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, reported a transaction involving the sale of common stock to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Dennis Cho, Senior Vice President at Twist Bioscience, sold shares to cover tax obligations related to vested Restricted Stock Units.

Twist Bioscience Corporation announces robust fiscal year 2025 financial performance, including record revenue and improved gross margin, ahead of its 2026 Annual Meeting of Stockholders.

Twist Bioscience is asking stockholders to approve increasing the number of authorized shares and providing officer exculpation at the upcoming annual meeting.

William Blair Investment Management, LLC has reported an 8.6% beneficial ownership stake in Twist Bioscience Corp.

Vanguard Capital Management has reported beneficial ownership of 5.05% of Twist Bioscience Corp.'s common stock as of March 31, 2026.

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting beneficial ownership of 10.35% of Twist Bioscience Corp. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Twist Bioscience Corp following an internal realignment.

Artisan Partners Asset Management Inc. and its affiliates report a 10.1% beneficial ownership stake in Twist Bioscience Corporation common stock.

William Blair Investment Management, LLC has reported an increased beneficial ownership of 9.7% in Twist Bioscience Corp, holding 5,954,429 shares of common stock.